NASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free XENE Stock Alerts $42.93 -0.50 (-1.15%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$42.18▼$43.2150-Day Range$39.50▼$47.2052-Week Range$27.99▼$50.99Volume113,596 shsAverage Volume391,224 shsMarket Capitalization$3.24 billionP/E RatioN/ADividend YieldN/APrice Target$59.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Xenon Pharmaceuticals alerts: Email Address Xenon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside38.5% Upside$59.44 Price TargetShort InterestHealthy3.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 8 Articles This WeekInsider TradingSelling Shares$931,940 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.04) to ($3.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.63 out of 5 starsMedical Sector385th out of 905 stocksPharmaceutical Preparations Industry174th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Xenon Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.47% of the outstanding shares of Xenon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently decreased by 5.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XENE. Previous Next 2.4 News and Social Media Coverage News SentimentXenon Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Xenon Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest6 people have searched for XENE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $931,940.00 in company stock.Percentage Held by InsidersOnly 5.43% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xenon Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.04) to ($3.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -15.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -15.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xenon Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Xenon Pharmaceuticals Stock (NASDAQ:XENE)Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.Read More XENE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XENE Stock News HeadlinesMay 8, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024May 8, 2024 | globenewswire.comPolarean's Xenon MRI to be Featured at Upcoming ATS 2024 ConferenceMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.May 8, 2024 | americanbankingnews.comXenon Pharmaceuticals (XENE) Scheduled to Post Earnings on ThursdayMay 7, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 2, 2024 | globenewswire.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate UpdateMay 2, 2024 | americanbankingnews.comStock Traders Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)April 16, 2024 | globenewswire.comXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingMay 8, 2024 | Behind the Markets (Ad)The Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.April 10, 2024 | investing.comXenon Pharmaceuticals Inc (XENE)April 10, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 4, 2024 | globenewswire.comXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 21, 2024 | money.usnews.comXenon Pharmaceuticals IncMarch 19, 2024 | finance.yahoo.comXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth PlansMarch 16, 2024 | finance.yahoo.comXENE Apr 2024 47.500 putMarch 12, 2024 | globenewswire.comXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysMarch 9, 2024 | finance.yahoo.comInsider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...March 5, 2024 | globenewswire.comXenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024March 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline ProgressMarch 2, 2024 | seekingalpha.comXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finanznachrichten.deXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 1, 2024 | markets.businessinsider.comBuy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in NeuroscienceFebruary 29, 2024 | finance.yahoo.comXenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comXenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 22, 2024 | globenewswire.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateFebruary 21, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: February EditionSee More Headlines Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/08/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XENE CUSIPN/A CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees251Year FoundedN/APrice Target and Rating Average Stock Price Target$59.44 High Stock Price Target$65.00 Low Stock Price Target$51.00 Potential Upside/Downside+38.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-182,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.18% Return on Assets-23.99% Debt Debt-to-Equity RatioN/A Current Ratio23.65 Quick Ratio23.65 Sales & Book Value Annual Sales$9.43 million Price / Sales343.53 Cash FlowN/A Price / Cash FlowN/A Book Value$14.18 per share Price / Book3.03Miscellaneous Outstanding Shares75,460,000Free Float71,365,000Market Cap$3.24 billion OptionableOptionable Beta1.19 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Ian C. Mortimer C.M.A. (Age 48)CPA, M.B.A., President, CEO & Director Comp: $973.76kMs. Sherry Aulin (Age 40)Chief Financial Officer Comp: $3.03MMs. Andrea DiFabio J.D. (Age 56)Chief Legal Officer & Corporate Secretary Comp: $200.51kDr. Christopher E. Von Seggern M.B.A. (Age 45)M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer Comp: $618.07kDr. Christopher John Kenney M.D. (Age 53)Chief Medical Officer Comp: $684.22kMs. Shelley McCloskey B.A. (Age 64)Executive Vice President of Human Resources Dr. Robin P. Sherrington Ph.D. (Age 63)Executive Vice President of Strategy & Innovation Comp: $351.67kDr. James R. Empfield Ph.D. (Age 63)Executive Vice President of Drug Discovery Comp: $323.43kMs. Sheila M. Grant M.B.A.M.Sc., MBA, Executive Vice President of R&D OperationsMore ExecutivesKey CompetitorsIDEAYA BiosciencesNASDAQ:IDYAJanux TherapeuticsNASDAQ:JANXHUTCHMEDNASDAQ:HCMArrowhead PharmaceuticalsNASDAQ:ARWRAmicus TherapeuticsNASDAQ:FOLDView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Bought 3,813 shares on 5/8/2024Ownership: 0.236%ProShare Advisors LLCBought 565 shares on 5/8/2024Ownership: 0.007%TimesSquare Capital Management LLCSold 56,781 shares on 5/7/2024Ownership: 0.977%SG Americas Securities LLCBought 1,760 shares on 5/7/2024Ownership: 0.027%Oppenheimer Asset Management Inc.Bought 946 shares on 5/7/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions XENE Stock Analysis - Frequently Asked Questions Should I buy or sell Xenon Pharmaceuticals stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XENE shares. View XENE analyst ratings or view top-rated stocks. What is Xenon Pharmaceuticals' stock price target for 2024? 9 equities research analysts have issued 1-year target prices for Xenon Pharmaceuticals' stock. Their XENE share price targets range from $51.00 to $65.00. On average, they expect the company's share price to reach $59.44 in the next twelve months. This suggests a possible upside of 38.5% from the stock's current price. View analysts price targets for XENE or view top-rated stocks among Wall Street analysts. How have XENE shares performed in 2024? Xenon Pharmaceuticals' stock was trading at $46.06 at the beginning of 2024. Since then, XENE shares have decreased by 6.8% and is now trading at $42.93. View the best growth stocks for 2024 here. When is Xenon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our XENE earnings forecast. How can I listen to Xenon Pharmaceuticals' earnings call? Xenon Pharmaceuticals will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its quarterly earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.12. The firm's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.57) EPS. What ETFs hold Xenon Pharmaceuticals' stock? ETFs with the largest weight of Xenon Pharmaceuticals (NASDAQ:XENE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Fidelity Disruptive Medicine ETF (FMED), BlackRock Future Health ETF (BMED), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), BNY Mellon Innovators ETF (BKIV) and Goldman Sachs Future Health Care Equity ETF (GDOC). What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI). Who are Xenon Pharmaceuticals' major shareholders? Xenon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include TimesSquare Capital Management LLC (0.98%), Jennison Associates LLC (0.75%), Assenagon Asset Management S.A. (0.25%), Russell Investments Group Ltd. (0.24%), GSA Capital Partners LLP (0.03%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin, Simon N Pimstone and Steven Gannon. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XENE) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.